ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0415

The Association of Early TNF Inhibitor Use with Incident Cardiovascular Events in Ankylosing Spondylitis

Jean Liew1, Timothy Treu2, yojin Park2, Jacqueline Ferguson3, Morgan Rosser2, yuk-Lam Ho2, Susan Heckbert4, Lianne Gensler5, Katherine Liao6 and Maureen Dubreuil7, 1Boston University School of Medicine, Boston, MA, 2VA Boston Healthcare System, Boston, MA, 3Stanford, Palo Alto, CA, 4University of Washington, Seattle, WA, 5Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, 6Brigham and Women's Hospital, Boston, MA, 7Department of Rheumatology, Boston University School of Medicine, Boston, MA

Meeting: ACR Convergence 2022

Keywords: Ankylosing spondylitis (AS), Cardiovascular, Epidemiology, Pharmacoepidemiology, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Spondyloarthritis Including PsA – Treatment Poster I: AxSpA

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: The increased cardiovascular (CV) disease burden in ankylosing spondylitis (AS) is established. Whether tumor necrosis factor inhibitor (TNFi) treatment, particularly when started early in the disease course, is cardioprotective is unclear. The aim of our study was to test the association of early TNFi use with incident CV outcomes in an AS cohort.

Methods: We studied a cohort of 17,666 patients with AS within the Veterans Affairs Corporate Data Warehouse between 2002-2019. AS was defined as ≥1 inpatient or ≥2 outpatient ICD codes for AS, at least six weeks apart. Any TNFi use was determined from pharmacy dispense and infusion data. Early TNFi exposure was assessed in the 12-month period following the index date (date of first AS ICD code). The primary outcome was any incident CV disease identified using ICD codes for coronary artery disease, myocardial infarction (MI), or ischemic stroke. Secondary outcomes were MI, venous thromboembolism (VTE), stroke, major adverse cardiovascular events (MACE) including MI, stroke, and CV death, and all-cause mortality. Follow-up started at 12 months after the index date for all subjects until CV event, death, disenrollment, or end of study (December 2019). Those with ≥1 ICD codes for rheumatoid arthritis within one year before AS diagnosis were excluded to improve cohort specificity.

We calculated propensity scores to estimate the probability of a patient starting a TNFi for AS, given the patient characteristics in the 12 months prior to the index date. We fit Cox proportional hazards models with inverse probability weights based on these propensity scores to estimate the risk of each CV outcome with early TNFi initiation compared to non-initiation. Analyses were performed in the overall cohort, and separately in two calendar periods (2002-2010, 2011-2019) to account for secular trends in AS and CV management.

Results: We identified 17,666 individuals with an incident diagnosis of AS (mean age 59.5 years, 91.2% male, 79.8% white), of whom 2,321 were early TNFi initiators and 15,345 were non-TNFi initiators (Table). Mean follow-up was 6.0±4.4 years. TNFi initiators were younger with a lower prevalence of hypertension and diabetes compared to non-TNFi initiators. During follow-up 351 (15.1%) TNFi initiators had incident CVD compared to 3020 (19.7%) non- initiators.

In the propensity score analysis, early TNFi initiation was associated with higher risk of incident CVD (HR 1.17, 95% CI 1.01-1.35), stroke (HR 1.24, 95% CI 1.03-1.50), and MACE (HR 1.22, 95% CI 1.03-1.45) in the cohort overall (Figure). These associations were also demonstrated in calendar period 2011-2019.

Conclusion: In this AS cohort, subjects who initiated TNFi early in their disease course compared to no initiation had a higher risk of incident CVD, and risk of stroke and MACE individually. Although this may represent a true effect, residual confounding by indication cannot be excluded.

Supporting image 2

Title: Adjusted hazard ratios for primary and secondary outcomes and early TNFi initiation with among 17,666 individuals with AS between 2002_2019 within the Veterans Affairs Corporate Data Warehouse

Figure caption: Adjusted HR and 95% CI are presented for all outcomes in the cohort overall and stratified by calendar periods (2002_2010, 2011_2019). Cox proportional hazards models with inverse probability weighting based on the propensity of TNFi initiation within 12 months following the index date given demographics, comorbidities (hypertension, chronic kidney disease, prior coronary heart disease, prior stroke), NSAID use, glucocorticoid use, non-TNFi disease modifying antirheumatic drug use, spinal imaging orders, physical therapy referrals, referrals to pain clinic/acupuncture/chiropractor, primary care visits, rheumatology visits, and emergency department/urgent care visits in the 12 months prior to the index date. Models additionally adjusted for age as a quadratic term, DMARD use, and rheumatology visits. Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; CVD, cardiovascular disease; MI, myocardial infarction; VTE, venous thromboembolism; MACE, major adverse cardiac events


Disclosures: J. Liew, None; T. Treu, None; y. Park, None; J. Ferguson, None; M. Rosser, None; y. Ho, None; S. Heckbert, None; L. Gensler, Novartis, Pfizer Inc, UCB Pharma, AbbVie, Eli Lilly, Janssen, Gilead, Moonlake; K. Liao, None; M. Dubreuil, Amgen, UCB Pharma, Pfizer.

To cite this abstract in AMA style:

Liew J, Treu T, Park y, Ferguson J, Rosser M, Ho y, Heckbert S, Gensler L, Liao K, Dubreuil M. The Association of Early TNF Inhibitor Use with Incident Cardiovascular Events in Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-association-of-early-tnf-inhibitor-use-with-incident-cardiovascular-events-in-ankylosing-spondylitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-association-of-early-tnf-inhibitor-use-with-incident-cardiovascular-events-in-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology